Licensing Opportunity: Improved Antibiotic Therapy of Mycobacterium Tuberculosis

Licensing Opportunity:

Improved Antibiotic Therapy of Mycobacterium Tuberculosis

Scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB. Credit: NIAID

NIAID researchers have discovered a treatment for tuberculosis infection that may improve a body’s ability to clear and control the bacteria. It was found using a mouse model that heme oxygenase-1 (HO-1) inhibitors enhance bacterial clearance when used with conventional antibiotic therapy, resulting in a marked improvement in pulmonary bacterial control. This host-directed strategy does not directly target the pathogen itself but may have an added advantage as a treatment for infections with antibiotic-resistant Mtb strains.

Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-174-2016. 

Follow NIAID Tech Transfer on LinkedIn